The US FDA's Oncologic Drugs Advisory Committee's 10-3 recommendation for the approval of Emmaus Life Sciences Inc.'s sickle cell disease candidate L-glutamine shows that a strong safety profile and unmet clinical need can overcome questionable imputation methods and a modest showing of efficacy.
This is a strong endorsement for the company's product, as FDA had previously put forth several concerns about the clinical data. The sponsor saw a higher than expected dropout rate in the treatment arm of its main Phase III trial, and used an extrapolation method to fill those holes deemed "inappropriate" by the agency
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?